Supect (radotinib) / R-Pharm, IL-Yang Pharm 
Welcome,         Profile    Billing    Logout  

4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Supect (radotinib) / IL-Yang Pharm
NCT03722420: Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)

Active, not recruiting
3
238
RoW
Radotinib, Supect, Imatinib, Glivec
Il-Yang Pharm. Co., Ltd.
Chronic Myeloid Leukemia, Chronic Phase
03/23
06/25
NCT03459534: A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs

Recruiting
3
173
RoW
Radotinib HCl, SUPECT
Il-Yang Pharm. Co., Ltd.
Chronic Myeloid Leukemia, Chronic Phase, CML, Chronic Phase, CML, Refractory, CML - Philadelphia Chromosome
01/25
04/25
NCT04691661: Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease

Recruiting
2
40
Europe
Radotinib HCl 50 mg, Radotinib, IY5511, Placebo
Il-Yang Pharm. Co., Ltd.
Parkinson Disease
12/25
12/26
NCT06461078: Clinical Trial to Investigate the Effects of Food on the Pharmacokinetics and Safety of Orally Administered Radotinib

Not yet recruiting
1
24
RoW
Radotinib HCl, SUPECT
Il-Yang Pharm. Co., Ltd.
Drug Kinetics
09/24
06/25

Download Options